Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from HC Wainwright

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright also issued estimates for Context Therapeutics’ Q3 2025 earnings at ($0.05) EPS and Q4 2025 earnings at ($0.05) EPS.

Several other equities research analysts also recently commented on CNTX. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Wednesday, January 15th. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. Finally, JMP Securities began coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 target price for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $6.17.

Context Therapeutics Trading Up 0.2 %

NASDAQ:CNTX opened at $0.77 on Friday. Context Therapeutics has a 12 month low of $0.64 and a 12 month high of $2.75. The firm has a fifty day simple moving average of $0.85 and a 200-day simple moving average of $1.44. The company has a market capitalization of $57.88 million, a P/E ratio of -0.85 and a beta of 2.06.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. Equities analysts forecast that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. MPM Bioimpact LLC purchased a new position in Context Therapeutics in the fourth quarter valued at $15,441,000. Blue Owl Capital Holdings LP increased its holdings in Context Therapeutics by 17.5% in the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock valued at $6,676,000 after buying an additional 946,638 shares in the last quarter. Franklin Resources Inc. increased its holdings in Context Therapeutics by 115.9% in the fourth quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company’s stock valued at $4,204,000 after buying an additional 2,149,392 shares in the last quarter. Allostery Investments LP purchased a new position in Context Therapeutics in the fourth quarter valued at $998,000. Finally, Geode Capital Management LLC increased its holdings in Context Therapeutics by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after buying an additional 52,830 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.